Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127046872 | 12704687 | 2 | F | 20160822 | 20160831 | 20160901 | EXP | US-ELI_LILLY_AND_COMPANY-US201503004255 | ELI LILLY AND CO | 0.00 | M | Y | 0.00000 | 20160901 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127046872 | 12704687 | 1 | PS | ZYPREXA | OLANZAPINE | 1 | Oral | 2.5 MG, AT BEDTIME | U | U | 20592 | 2.5 | MG | ||||||
| 127046872 | 12704687 | 2 | SS | ZYPREXA | OLANZAPINE | 1 | Oral | 5 MG, AT BEDTIME | U | U | 20592 | 5 | MG | ||||||
| 127046872 | 12704687 | 3 | SS | ZYPREXA | OLANZAPINE | 1 | Oral | 10 MG, AT BEDTIME | U | U | 20592 | 10 | MG | ||||||
| 127046872 | 12704687 | 4 | SS | ZYPREXA | OLANZAPINE | 1 | Oral | 20 MG, AT BEDTIME | U | U | 20592 | 20 | MG | ||||||
| 127046872 | 12704687 | 5 | SS | ZYPREXA | OLANZAPINE | 1 | Oral | 7.5 MG, AT BEDTIME | U | U | 20592 | 7.5 | MG | ||||||
| 127046872 | 12704687 | 6 | C | TRAZODONE | TRAZODONE HYDROCHLORIDE | 1 | Oral | 50 MG, PRN | 0 | 50 | MG | ||||||||
| 127046872 | 12704687 | 7 | C | COCAINE | COCAINE | 1 | 0 | ||||||||||||
| 127046872 | 12704687 | 8 | C | PAXIL | PAROXETINE HYDROCHLORIDE | 1 | Unknown | UNK, UNKNOWN | 0 | ||||||||||
| 127046872 | 12704687 | 9 | C | PAXIL | PAROXETINE HYDROCHLORIDE | 1 | Unknown | 60 MG, QD | 0 | 60 | MG | QD | |||||||
| 127046872 | 12704687 | 10 | C | PAXIL | PAROXETINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127046872 | 12704687 | 11 | C | LOVASTATIN. | LOVASTATIN | 1 | Oral | 40 MG, QD | 0 | 40 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127046872 | 12704687 | 1 | Psychotic disorder |
| 127046872 | 12704687 | 6 | Insomnia |
| 127046872 | 12704687 | 8 | Anxiety |
| 127046872 | 12704687 | 9 | Depression |
| 127046872 | 12704687 | 10 | Obsessive-compulsive disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127046872 | 12704687 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127046872 | 12704687 | Anxiety | |
| 127046872 | 12704687 | Binge eating | |
| 127046872 | 12704687 | Bipolar disorder | |
| 127046872 | 12704687 | Gynaecomastia | |
| 127046872 | 12704687 | Hyperlipidaemia | |
| 127046872 | 12704687 | Memory impairment | |
| 127046872 | 12704687 | Obsessive-compulsive disorder | |
| 127046872 | 12704687 | Road traffic accident | |
| 127046872 | 12704687 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127046872 | 12704687 | 1 | 20080211 | 0 | ||
| 127046872 | 12704687 | 5 | 20080721 | 0 | ||
| 127046872 | 12704687 | 6 | 20080707 | 0 | ||
| 127046872 | 12704687 | 8 | 2004 | 0 |